Eli Lilly data compare favorably to Mounjaro, Ozempic, says Deutsche Bank

Deutsche Bank says Eli Lilly’s (LLY) retatrutide showed absolute estimated weight loss of 15% or 13% placebo-adjusted, which compares favorably to Mounjaro’s SURPASS-1 and Ozempic’s SUSTAIN-1 trials. Retatrutide also looks better than high-dose semaglutide’s OASIS-1 results on weight-loss despite having lower baseline body mass index and both enrolling 50% female patients, the analyst tells investors in a research note. Deutsche thinks the results carve out a type 2 diabetes “niche” for the drug. The firm has a Buy rating on Lilly shares with a $1,285 price target